RESUMEN
Percutaneous intramedullary fixation may provide an ideal method for stabilization of bone fractures, while avoiding the need for large tissue dissections. Tibiae in 18 sheep were treated with an intramedullary photodynamic bone stabilization system (PBSS) that comprised a polyethylene terephthalate (Dacron) balloon filled with a monomer, cured with visible light in situ, and then harvested at 30, 90, or 180 days. In additional 40 sheep, a midshaft tibial osteotomy was performed and stabilized with external fixators or external fixators combined with the PBSS and evaluated at 8, 12, and 26 weeks. Healing and biocompatibility were evaluated by radiographic analysis, micro-computed tomography, and histopathology. In nonfractured sheep tibiae, PBSS implants conformably filled the medullary canal, while active cortical bone remodeling and apposition of new periosteal and/or endosteal bone was observed with no significant macroscopic or microscopic observations. Fractured sheep tibiae exhibited increased bone formation inside the osteotomy gap, with no significant difference when fixation was augmented by PBSS implants. Periosteal callus size gradually decreased over time and was similar in both treatment groups. No inhibition of endosteal bone remodeling or vascularization was observed with PBSS implants. Intramedullary application of a light-curable PBSS is a biocompatible, feasible method for fracture fixation.
Asunto(s)
Sustitutos de Huesos , Fijadores Externos , Curación de Fractura , Luz , Fracturas de la Tibia/terapia , Animales , Sustitutos de Huesos/efectos adversos , Sustitutos de Huesos/química , Sustitutos de Huesos/farmacología , Evaluación Preclínica de Medicamentos , Ensayo de Materiales/métodos , OvinosRESUMEN
BACKGROUND: Dabigatran and rivaroxaban are new oral anticoagulants that are eliminated through the kidneys. Their use in dialysis patients is discouraged because these drugs can bioaccumulate to precipitate inadvertent bleeding. We wanted to determine whether prescription of dabigatran or rivaroxaban was occurring in the dialysis population and whether these practices were safe. METHODS AND RESULTS: Prevalence plots were used to describe the point prevalence (monthly) of dabigatran and rivaroxaban use among 29977 hemodialysis patients with atrial fibrillation. Poisson regression compared the rate of bleeding, stroke, and arterial embolism in patients who started dabigatran, rivaroxaban, or warfarin. The first record of dabigatran prescription among hemodialysis patients occurred 45 days after the drug became available in the United States. Since then, dabigatran and rivaroxaban use in the atrial fibrillation-end-stage renal disease population has steadily risen where 5.9% of anticoagulated dialysis patients are started on dabigatrian or rivaroxaban. In covariate adjusted Poisson regression, dabigatran (rate ratio, 1.48; 95% confidence interval, 1.21-1.81; P=0.0001) and rivaroxaban (rate ratio, 1.38; 95% confidence interval, 1.03-1.83; P=0.04) associated with a higher risk of hospitalization or death from bleeding when compared with warfarin. The risk of hemorrhagic death was even larger with dabigatran (rate ratio, 1.78; 95% confidence interval, 1.18-2.68; P=0.006) and rivaroxaban (rate ratio, 1.71; 95% confidence interval, 0.94-3.12; P=0.07) relative to warfarin. There were too few events in the study to detect meaningful differences in stroke and arterial embolism between the drug groups. CONCLUSIONS: More dialysis patients are being started on dabigatran and rivaroxaban, even when their use is contraindicated and there are no studies to support that the benefits outweigh the risks of these drugs in end-stage renal disease.
Asunto(s)
Anticoagulantes/uso terapéutico , Fibrilación Atrial/tratamiento farmacológico , Bencimidazoles/uso terapéutico , Fallo Renal Crónico/complicaciones , Morfolinas/uso terapéutico , Pautas de la Práctica en Medicina/estadística & datos numéricos , Diálisis Renal , Tiofenos/uso terapéutico , beta-Alanina/análogos & derivados , Anciano , Anciano de 80 o más Años , Anticoagulantes/efectos adversos , Anticoagulantes/farmacocinética , Fibrilación Atrial/complicaciones , Fibrilación Atrial/metabolismo , Bencimidazoles/efectos adversos , Bencimidazoles/farmacocinética , Dabigatrán , Bases de Datos Factuales , Relación Dosis-Respuesta a Droga , Utilización de Medicamentos , Femenino , Hemorragia/inducido químicamente , Hemorragia/epidemiología , Hospitalización/estadística & datos numéricos , Humanos , Riñón/efectos de los fármacos , Riñón/metabolismo , Fallo Renal Crónico/metabolismo , Masculino , Análisis por Apareamiento , Persona de Mediana Edad , Morfolinas/efectos adversos , Morfolinas/farmacocinética , Distribución de Poisson , Pautas de la Práctica en Medicina/tendencias , Estudios Retrospectivos , Riesgo , Rivaroxabán , Accidente Cerebrovascular/etiología , Tiofenos/efectos adversos , Tiofenos/farmacocinética , Warfarina/efectos adversos , Warfarina/farmacocinética , Warfarina/uso terapéutico , beta-Alanina/efectos adversos , beta-Alanina/farmacocinética , beta-Alanina/uso terapéuticoRESUMEN
Natural products including botanicals for both therapy of clinical manifestations of atherosclerosis and reduction of atherosclerosis risk factors are topics of recent patents. Only a few recent patents are relevant to the direct antiatherosclerotic therapy leading to regression of atherosclerotic lesions. Earlier, using a cellular model we have developed and patented several anti-atherosclerotic drugs. The AMAR (Atherosclerosis Monitoring and Atherogenicity Reduction) study was designed to estimate the effect of two-year treatment with time-released garlic-based drug Allicor on the progression of carotid atherosclerosis in 196 asymptomatic men aged 40-74 in double-blinded placebo-controlled randomized clinical study. The primary outcome was the rate of atherosclerosis progression, measured by high-resolution B-mode ultrasonography as the increase in carotid intima-media thickness (IMT) of the far wall of common carotid arteries. The mean rate of IMT changes in Allicor-treated group (-0.022±0.007 mm per year) was significantly different (P = 0.002) from the placebo group in which there was a moderate progression of 0.015±0.008 mm at the overall mean baseline IMT of 0.931±0.009 mm. A significant correlation was found between the changes in blood serum atherogenicity (the ability of serum to induce cholesterol accumulation in cultured cells) during the study and the changes in intima-media thickness of common carotid arteries (r = 0.144, P = 0.045). Thus, the results of AMAR study demonstrate that long-term treatment with Allicor has a direct anti-atherosclerotic effect on carotid atherosclerosis and this effect is likely to be due to serum atherogenicity inhibition. The beneficial effects of other botanicals including Inflaminat (calendula, elder and violet), phytoestrogen- rich Karinat (garlic powder, extract of grape seeds, green tea leafs, hop cones, ß-carotene, α-tocopherol and ascorbic acid) on atherosclerosis have also been revealed in clinical studies which enforces a view that botanicals might represent promising drugs for anti-atherosclerotic therapy.
Asunto(s)
Fármacos Cardiovasculares/uso terapéutico , Enfermedades de las Arterias Carótidas/tratamiento farmacológico , Ajo , Preparaciones de Plantas/uso terapéutico , Adulto , Anciano , Ácido Ascórbico/uso terapéutico , Biomarcadores/sangre , Enfermedades de las Arterias Carótidas/sangre , Enfermedades de las Arterias Carótidas/diagnóstico por imagen , Grosor Intima-Media Carotídeo , Colesterol/sangre , Progresión de la Enfermedad , Método Doble Ciego , Humanos , Masculino , Persona de Mediana Edad , Fitoterapia , Plantas Medicinales , Factores de Tiempo , Resultado del Tratamiento , alfa-Tocoferol/uso terapéutico , beta Caroteno/uso terapéuticoRESUMEN
PURPOSE OF REVIEW: The purpose of this review is to summarize the role of endothelial shear stress in the natural history of coronary atherosclerosis, and to propose an individualized risk-stratification strategy of atherosclerotic lesions based on the in-vivo characterization of local endothelial shear stress and wall morphology. RECENT FINDINGS: Low endothelial shear stress promotes the development of early fibroatheromas, which subsequently follow an individualized natural history of progression. This individual natural history is critically dependent on the magnitude of low endothelial shear stress, which subsequently regulates the severity of inflammation within the wall and ultimately the vascular remodeling response. Very low endothelial shear stress enhances plaque inflammation, leading to excessive expansive remodeling. Excessive expansive remodeling leads to perpetuation, or even exacerbation, of the local low endothelial shear stress environment, thereby setting up a self-perpetuating vicious cycle among low local endothelial shear stress, inflammation, and excessive expansive remodeling, which transforms an early fibroatheroma to a high-risk plaque. SUMMARY: In-vivo assessment of the local endothelial shear stress environment, severity of inflammation and vascular remodeling response, all responsible for individual plaque behavior and natural history, in combination with systemic biomarkers of vulnerability, may allow for detailed risk stratification of individual early atherosclerotic plaques, thereby guiding both systemic and local, lesion-specific therapeutic strategies.